The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vectorized gene therapy of liver tumors: Safety and proof of concept of TG4023 (MVA-FCU1)/5-FC combination.
Faress Husseini
Research Funding - Transgene S.A. (B)
Jean-Pierre Delord
Consultant or Advisory Role - Roche
Research Funding - Transgene S.A.
Cécile Fournel-Frederico
Research Funding - Transgene S.A.
Jean-Emmanuel Kurtz
Research Funding - Transgene S.A.
Philippe Erbs
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Michel Homerin
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Céline Halluard
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Chloé Jemming
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Clélia Orange
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Jean-Marc Limacher
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.